Canaccord analyst Edward Nash raised the firm’s price target on Ventyx Biosciences to $54 from $35 and keeps a Buy rating on the shares. The analyst noted the company currently has four Phase II studies in multiple indications ongoing, and initial top-line data are anticipated in 2H 2023. Ventyx also announced two new additions to the company’s product pipeline: an extended release (ER) formulation of VTX958, which is in final optimization with an in-human study planned for 1H23, and an IL-4Ralpha antagonist that is in early-stage development; keeping Canaccord bullish on the shares.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on VTYX:
- Ventyx Biosciences remains Best Idea after R&D Day, says Piper Sandler
- Ventyx Biosciences price target raised to $65 from $50 at Evercore ISI
- Ventyx Biosciences announces pipeline updates, strategic priorities
- Ventyx Biosciences Announces Pipeline Updates and Highlights Strategic Priorities at Investor R&D Day
- Ventyx Biosciences management to meet with Piper Sandler